FDA Approves Pfizer ’s Bosulif (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML)

December 19, 2017 -- Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to expand the indication for Bosulif (bosutinib) to include adult patients with...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news